Skip to main content

Glucagon-Like Peptide-1 Receptor Agonists & Intentional Self-Harm

Basic Details
Status
Ongoing
Last Updated
Thursday, February 12, 2026
Original Posting Date
Health Outcome(s)
intentional self-harm
Purpose
Drug and Outcome Analysis
Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR
No
Analytic Code Link(s) (3)
Sentinel Analytic Package: Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Obesity: A Descriptive Analysis Sentinel Analytic Package: Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes: An Inverse Probability of Treatment Weighting Analysis Sentinel Analytic Package: Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes, By Age and Sex Subgroups: An Inverse Probability of Treatment Weighting Analysis
Result(s) (5)
Intentional Self-Harm Following Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RA) Use in Patients with Diabetes & Obesity: A Descriptive Analysis Intentional Self-Harm Following Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists Use in Patients 18 Years and Older: A Descriptive Analysis Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Obesity: A Descriptive Analysis Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes: An Inverse Probability of Treatment Weighting Analysis Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes, By Age and Sex Subgroups: An Inverse Probability of Treatment Weighting Analysis
Regulatory Link(s) (2)
FDA Safety Communication: Update on FDA's Ongoing Evaluation of Reports of Suicidal Thoughts or Actions in Patients Taking a Certain Type of Medicines Approved for Type 2 Diabetes and Obesity FDA Safety Communication: FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications